References
- Ahmed S R, Brooman P JG, Shalet S M, Howell A, Blacklock N J, Richards D. Treatment of advanced prostatic cancer with the LHRH analogue ICI 118630: clinical response and hormonal mechanism. Lancet 1983; 2: 415–418
- Allen J M, O'Shea J P, Mashiter K, Williams G, Bloom S R. Advanced carcinoma of the prostate: treatment with a gonadotropin releasing hormone agonist. Br Med J 1983; 286: 1607
- Lunglmeyer G, Girsch E. Patient choice in the treatment of advanced prostate cancer. International Congress and Symposium Series, G D Chisholm, London 1987; 47–51
- Parmer H, Edwards L, Philips R H, Allen L, Lightman S L. Orchidectomy versus long acting D-Trp-6-LHRH in advanced prostatic cancer. Br J Urol 1978; 59: 248
- Samdal F, Vada K, Lundmo P I, Teigum H, Brevik B, Mjølnerød O K. Orchidectomy eller Zoladex i behandlingen av cancer prostata—hva foretrekker pasientene?. Vitenskapelige forhandlinger, H O Breisland, Oslo 1989; 196
- Smith J A, Glode L ML, Wettlaufer J N, et al. Clinical effects of gonadotrophin-releasing hormone analogue in metastatic carcinoma of prostate. Urology 1985; 25: 106
- Wenderoth U K, Jacobi G H. Gonadotropin releasing hormone analogues for the palliation of the carcinoma of the prostate. World J Urol 1983; 1: 40